{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:50:25Z","timestamp":1784137825681,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T00:00:00Z","timestamp":1688860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.prro.2023.05.012","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T15:46:30Z","timestamp":1689090390000},"page":"540-550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2120-1939","authenticated-orcid":false,"given":"Krishnan R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Rydzewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Cooley-Zgela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich P.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Lindenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah E.","family":"Citrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2023.05.012_bib0001","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.05.012_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2021.07.930","article-title":"Patterns of failure in men with radiorecurrent prostate cancer: A post-hoc analysis of two prospective Ga-68-PSMA PET\/CT imaging trials","volume":"111","author":"Smith","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.012_bib0003","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2022.02.014","article-title":"Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage","volume":"169","author":"Maitre","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.05.012_bib0005","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.012_bib0006","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.prro.2023.05.012_bib0007","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/01621459.1946.10501898","article-title":"The statistical sign test","volume":"41","author":"Dixon","year":"1946","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.prro.2023.05.012_bib0008","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.prro.2023.05.012_bib0009","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2017.11.007","article-title":"Robotic stereotactic retreatment for biochemical control in previously irradiated patients affected by recurrent prostate cancer","volume":"30","author":"Loi","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2023.05.012_bib0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2020.09.054","article-title":"Prostate stereotactic body radiation therapy: An overview of toxicity and dose response","volume":"110","author":"Wang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.012_bib0011","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.radonc.2017.03.006","article-title":"Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?","volume":"123","author":"Helou","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0012","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.prro.2016.07.004","article-title":"Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer","volume":"7","author":"Zhang","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0013","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.prro.2015.02.001","article-title":"Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Seymour","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus","volume":"98","author":"Jereczek-Fossa","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.prro.2023.05.012_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2007.03.008","article-title":"Accuracy of image-guided radiotherapy of prostate cancer based on the BeamCath urethral catheter technique","volume":"83","author":"Poulsen","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.916254","article-title":"Urethral interfractional geometric and dosimetric variations of prostate cancer patients: A study using an onboard MRI","volume":"12","author":"Pham","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0017","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.prro.2015.02.010","article-title":"Increased radiation dose heterogeneity within the prostate predisposes to urethral strictures in patients receiving moderately hypofractionated prostate radiation therapy","volume":"5","author":"McDonald","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0018","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","article-title":"Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer","volume":"108","author":"Bergamin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.012_bib0019","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2019.07.012","article-title":"Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: A retrospective multicenter study of the GETUG","volume":"105","author":"Pasquier","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.012_bib0020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13014-021-01839-w","article-title":"Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: The impact of castration sensitivity on treatment outcomes","volume":"16","author":"Lewin","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.861127","article-title":"A prospective study of high dose-rate brachytherapy or stereotactic body radiotherapy of intra-prostatic recurrence: Toxicity and long term clinical outcome","volume":"12","author":"Ryg","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026666","article-title":"GETUG-AFU 31: A phase I\/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol","volume":"09","author":"Pasquier","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.prro.2023.05.012_bib0023","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.prro.2015.04.009","article-title":"High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment","volume":"5","author":"Fuller","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0024","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-017-0833-9","article-title":"Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: Preliminary results of the Oscar Lambret Center","volume":"12","author":"Leroy","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0025","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group\/American College of Radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0026","article-title":"Effect of standard versus dose-escalated radiation therapy for patients with intermediate-risk prostate cancer","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0027","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0360-3016(99)00089-9","article-title":"Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX\/N0, M0) adenocarcinoma of the prostate","volume":"44","author":"Zagars","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.012_bib0028","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0029","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0030","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180494","article-title":"Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)","volume":"92","author":"Jereczek-Fossa","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2023.05.012_bib0031","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.ijrobp.2007.11.067","article-title":"Virtual HDR CyberKnife treatment for localized prostatic carcinoma: Dosimetry comparison with HDR brachytherapy and preliminary clinical observations","volume":"70","author":"Fuller","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.012_bib0032","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ijrobp.2019.02.041","article-title":"Reirradiation of locally recurrent prostate cancer with volumetric modulated arc therapy","volume":"104","author":"D'Agostino","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.012_bib0033","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150197","article-title":"Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer","volume":"88","author":"Zerini","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2023.05.012_bib0034","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2023.05.012_bib0035","first-page":"41","article-title":"Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET\/CT and multi-parametric MRI","volume":"32","author":"Liu","year":"2022","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023001716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023001716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T19:57:54Z","timestamp":1714593474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850023001716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1879850023001716"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2023.05.012","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2023.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}